|Bid||4.2500 x 3200|
|Ask||0.0000 x 1800|
|Day's range||4.1000 - 4.4350|
|52-week range||2.8200 - 5.2400|
|Beta (5Y monthly)||2.22|
|PE ratio (TTM)||N/A|
|Earnings date||09-Aug-2021 - 13-Aug-2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.80|
Spectrum Pharmaceuticals today presented an e-poster on poziotinib CNS activity in patients with NSCLC EGFR or HER2 exon 20 mutations at ASCO.
Spectrum Pharmaceuticals announces that the FDA is "on site" for the ROLONTIS® (eflapegrastim) manufacturing facility inspection.
Spectrum Pharmaceuticals to present poster for poziotinib in brain mets at upcoming ASCO Annual Meeting beginning on June 4 2021.